Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd (NY: CANF )

2.010 USD -0.030 (-1.47%)
Official Closing Price Updated: 8:00 PM EDT, May 10, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 234,233
Open 2.090
Bid (Size) 1.970 (7)
Ask (Size) 2.000 (1)
Prev. Close 2.040
Today's Range 1.970 - 2.090
52wk Range 1.510 - 4.390
Shares Outstanding 463,769,463
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021 
From Business Wire News Releases
Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021
Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 
From Business Wire News Releases

Performance

YTD
+11.05%
+11.05%
1 Month
-12.61%
-12.61%
3 Month
-11.06%
-11.06%
6 Month
+6.91%
+6.91%
1 Year
+11.05%
+11.05%

More News

Read More
Can-Fite Expands its Phase II COVID-19 Study to Europe
From Business Wire News Releases
Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates
From Business Wire News Releases
Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies
From Business Wire News Releases
Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million
From Business Wire News Releases
Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update
From Business Wire News Releases
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
From Business Wire News Releases
Can-Fite Expands Mid-Stage COVID-19 Study To Europe
Tags Europe Market News Covid/19
From Benzinga
Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model
From Business Wire News Releases
Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing
Tags Penny Stocks Benzinga Preclinical Phase
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]